Colorectal Cancer

The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone in heavily pretreated metastatic colorectal cancer.

Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.

An interim analysis of the phase 2 REGINA trial met predefined statistical criteria and suggests the need for further evaluation of the combination of regorafenib, nivolumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

In certain patients, surgical omission, radiotherapy omission, and immunotherapy are being explored.

Mark A. Lewis, MD, discussed the growing excitement of using dostarlimab for the treatment of colorectal cancer and explored ways to maximize its potential.

The FDA has approved adagrasib plus cetuximab for KRAS G12C metastatic colorectal cancer based on data from the KRYSTAL-1 study.

A clinical complete response was observed in all 42 patients with locally advanced mismatch repair–deficient rectal cancer who completed treatment with the dostarlimab in a phase 2 study.

PolyPEPI1018 given in combination with atezolizumab showed tolerability and induced immune responses in patients with relapsed/refractory microsatellite-stable metastatic colorectal cancer.

The addition of liver transplantation to chemotherapy led to improved overall survival at 5 years in patients with definitively unresectable colorectal cancer metastasis in the liver.

An FDA advisory committee recommends approval for a new blood test for colorectal cancer screening, potentially offering a more convenient option that could boost screening rates.

During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.

The FDA has approved ColoSense, a stool screening test with 93% accuracy for colon cancer in average-risk adults over the age of 45. This noninvasive option may boost early detection rates.

During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.

A phase 2/3 study of GRANITE vaccine in combination with standard therapy shows encouraging early signs of efficacy and safety in patients with metastatic microsatellite-stable colorectal cancer.

In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.

For Colorectal Cancer Awareness Month, Jedrzej Wykretowicz, MD, PhD, discussed the importance of early detection and taking steps towards the prevention of colorectal cancer.

The novel cell therapy A2B530 is the first logic-gated cell therapy aimed at selectively killing tumor cells and protecting healthy cells in colorectal cancer.

In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.

Adagrasib plus cetuximab as a potential treatment option addresses an unmet need in pretreated KRAS G12C-mutated colorectal cancer, offering hope for improved outcomes.

In this companion article, Dr Tanios Bekaii-Saab provides insights into effective management of patients with metastatic colorectal cancer.

A dual primary end point of progression-free survival in the phase 3 CheckMate-8HW trial evaluating nivolumab and ipilimumab in metastatic colorectal cancer has been met.

In an interview with Targeted Oncology, Chris Haqq, MD, PhD, discussed the potential use of cancer vaccines in patients with KRAS-mutated pancreatic and colon cancer.

In an interview with Targeted Oncology, City of Hope cancer center’s Marwan Fakih, MD, further discussed the findings from this phase 3 trial and future directions for evaluating this combination.

The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C mutations.

While a notable difference in the occurrence of adverse events was seen between patients treated with maximal tumor debulking and standard systemic therapy vs systemic therapy alone, health-related quality-of-life and fatigue scales showed no substantial differences over time.

Researchers identified different functions of groups of intraepithelial T cells (T-IELs) throughout the gastrointestinal tract, which could help inform future immunological treatment for patients with colorectal cancer.

The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.

The CRCdx RAS mutation detection kit was designed to detect 35 variants of KRAS and NRAS exon 2, 3, and 4 somatic mutations in patients with colorectal cancer.

Fam-trastuzumab deruxtecan-nxki was granted 2 breakthrough therapy designations by the FDA for its potential to fill a treatment gap for HER2-expressing tumors.

Treatment with an investigational mitochondrial inhibitor and bevacizumab has started in a phase 1b clinical trial of patients with previously-treated metastatic colorectal cancer.